TipRanks
Savara (DE:YB4P)
FRANKFURT:YB4P
Germany Market
YB4P
Savara
RESEARCH TOOLSreports

Savara (YB4P) Stock News & Sentiment

0 Followers
Savara: Buy Rating Reaffirmed as MOLBREEVI Advances Toward 2026 PDUFA; $10 Price Target Maintained
Premium
Ratings
Savara: Buy Rating Reaffirmed as MOLBREEVI Advances Toward 2026 PDUFA; $10 Price Target Maintained
2M ago
SVRA
Savara Earns Buy Rating on Strengthened Leadership and High Confidence in MOLBREEVI’s Regulatory Path and Commercial Potential
Premium
Ratings
Savara Earns Buy Rating on Strengthened Leadership and High Confidence in MOLBREEVI’s Regulatory Path and Commercial Potential
4M ago
SVRA
Savara Expands Share Capital and Updates Executive Leadership
Premium
Company Announcements
Savara Expands Share Capital and Updates Executive Leadership
4M ago
8K
SVRA
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
Premium
Ratings
Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
6M ago
SVRA
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
Premium
Ratings
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
7M ago
SVRA
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
Premium
Ratings
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
7M ago
SVRA
Savara Signs Long-Term Lease for New Headquarters
Premium
Company Announcements
Savara Signs Long-Term Lease for New Headquarters
7M ago
8K
SVRA
More DE:YB4P News >

YB4P News on the Web

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), AptarGroup (ATR) and Abbott Laboratories (ABT)
TipRanks News
Bullish
Savara (SVRA) Gets a Buy from Piper Sandler
TipRanks News
Neutral
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
TipRanks News
Neutral
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
The Motley Fool
Bullish
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)
TipRanks News
Neutral
Savara Earns Buy Rating on Strengthened Leadership and High Confidence in MOLBREEVI’s Regulatory Path and Commercial Potential
TipRanks News
Bullish
Savara Expands Share Capital and Updates Executive Leadership
TipRanks News
Neutral
Savara says CFO Dave Lowrance stepping down for health reasons
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
DE:YB4P
Sector Average
Media Buzz
This Week2 articles
Weekly Average0 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:YB4P’s Media Buzz Sentiment?
Currently, no data Available
What is DE:YB4P’s weekly average amount of articles?
Currently, no data Available
What is DE:YB4P’s News Sentiment?
100% of articles about DE:YB4P were positive this week, compared to its sector average of 91%.
    Healthcare Stocks that are Trending in the News
    IQVIQVIA Holdings
    GILDGilead Sciences
    ABBVAbbVie
    VRTXVertex Pharmaceuticals
    NVSNovartis
    Showing the stocks with the most bullish news sentiment over the past week